Davide Capodanno/X
Sep 4, 2025, 11:52
PARTHENOPE Trial: A New Benchmark in Risk Score Validation
Davide Capodanno, Professor of Cardiology at the University of Catania, editor-in-Chief of EuroIntervention, posted on X:
”I think I have a positive bias toward the PARTHENOPE trial, not only because I was part of the Steering Committee and deeply respect the work behind it, but also because it does something rarely done when validating risk scores: randomization. Usually, we see validation based on discrimination or area under the curve, but in reality, the true test of a score’s utility is whether randomization to a score-guided versus non–score-guided strategy makes a difference on clinical outcomes. Just think of how many scores we use every day that lack this kind of validation.”
Read more here.
Stay updated with Hemostasis Today.
-
Aug 16, 2026, 13:21Francois Roubille: New ESC Consensus on Inflammation in Coronary Syndromes
-
Aug 16, 2026, 13:05Neil Morgan: Submit Your Abstract for BSHT 2027
-
Aug 16, 2026, 12:50Heba Youssef: Can Cefoperazone Cause Coagulopathy?
-
Aug 16, 2026, 12:35Mohammad Alkhalil: Stroke Remains a Dreaded Complication in TAVI
-
Aug 16, 2026, 12:16Jeff Schaffnit: The Power of Community in Rare Blood Disorders
-
Aug 16, 2026, 12:03Fawaz AlOtaibi: Can AI Replace Contrast CTA for Vascular Screening?
-
Aug 16, 2026, 10:31Erhabor Osaro: Critical Issues to Consider During the Clinical Blood Transfusion Process
-
Aug 16, 2026, 10:14Juan Manuel Cisneros Carrasco: The Architects Behind the Blood Donation System
-
Aug 16, 2026, 10:06Honoring the Life and Legacy of Dr. Reed Pyeritz – GADA Canada